Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study Newsfile - Tue Nov 19, 6:52AM CST

--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Newsfile - Thu Nov 14, 5:00PM CST

Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future...

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Newsfile - Thu Nov 7, 9:16AM CST

Presenting new clinical data from Phio's on-going Phase 1b trialMarlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Newsfile - Fri Nov 1, 7:02AM CDT

Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm ESTMarlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO)...

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Newsfile - Thu Oct 24, 7:14AM CDT

New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...

PHIO : 2.47 (-2.37%)
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Newsfile - Fri Oct 18, 12:34PM CDT

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series Newsfile - Fri Oct 18, 7:14AM CDT

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference Newsfile - Wed Oct 16, 7:12AM CDT

PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...

PHIO : 2.47 (-2.37%)
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells Newsfile - Mon Oct 7, 7:12AM CDT

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp....

PHIO : 2.47 (-2.37%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Newsfile - Wed Oct 2, 7:12AM CDT

Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage...

PHIO : 2.47 (-2.37%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - Fri Nov 22, 6:00PM CST
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot